PMLive1h
AbbVie announces FDA approval of antibiotic combination for intra-abdominal infections
AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...
CIDRAP16h
Sexually transmitted infections continue to rise in Europe
A series of reports released today by the European Centre for Disease Prevention and Control (ECDC) show sexually transmitted ...
CIDRAP17h
FDA approves combination antibiotic for difficult-to-treat infections
Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment ...
Managed Healthcare Executive19h
FDA Approves Combination Antibiotic for Complicated Infections
Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.
Pharmaceutical Technology on MSN22h
FDA approves AbbVie’s Emblaveo for intra-abdominal infections
AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...
Contract Pharma23h
AbbVie’s EMBLAVEO Approved by FDA for Treatment of Complicated Intra-Abdominal Infections
Addresses the significant threat of antimicrobial resistance.
BioSpace23h
AbbVie Gets FDA Approval for New Antibiotic in the Face of Rising Resistance
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...
Infectious Disease Advisor23h
Emblaveo Approved for Intra-Abdominal Infections in Patients With Limited Options
The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.